STEADY-STATE DISPOSITION OF HYDROMORPHONE AND HYDROMORPHONE-3-GLUCURONIDE IN CANCER-PATIENTS

被引：0
|
作者：
BABUL, N [1 ]
HAGEN, N [1 ]
THIRLWELL, M [1 ]
DHALIWAL, H [1 ]
HARSANYI, Z [1 ]
DARKE, A [1 ]
机构：
[1] MONTREAL GEN HOSP,THUNDER BAY REG CANC CTR,TOM BAKER CANC CTR,MONTREAL,PQ,CANADA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 1995年 / 57卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：165 / 165
页数：1
相关论文
共 50 条
  • [21] ALCOHOL AND THE STEADY-STATE DISPOSITION KINETICS OF METHADONE IN RATS
    TOMMASELLO, AC
    ADIR, J
    JOURNAL OF STUDIES ON ALCOHOL, 1984, 45 (02): : 155 - 159
  • [22] The Conversion Ratio From Intravenous Hydromorphone to Oral Opioids in Cancer Patients
    Reddy, Akhila
    Vidal, Marieberta
    Stephen, Saneese
    Baumgartner, Karen
    Dost, Sara
    Ann Nguyen
    Heung, Yvonne
    Kwan, Simeon
    Wong, Angelique
    Pangemanan, Imelda
    Azhar, Ahsan
    Tayjasanant, Supakarn
    Rodriguez, Edenmae
    Waletich, Jessica
    Lim, Kyu-Hyoung
    Wu, Jimin
    Liu, Diane
    Williams, Janet
    Yennurajalingam, Sriram
    Bruera, Eduardo
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2017, 54 (03) : 280 - 288
  • [23] [H-3] PACLITAXEL DISPOSITION AND METABOLISM IN CANCER-PATIENTS
    WALLE, T
    WALLE, UK
    KUMAR, GN
    BHALLA, K
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (02) : 153 - 153
  • [24] TAXOL METABOLISM AND DISPOSITION IN CANCER-PATIENTS
    WALLE, T
    WALLE, UK
    KUMAR, GN
    BHALLA, KN
    DRUG METABOLISM AND DISPOSITION, 1995, 23 (04) : 506 - 512
  • [25] A PROSPECTIVE EVALUATION OF OPTIMAL SAMPLING THEORY IN THE DETERMINATION OF THE STEADY-STATE PHARMACOKINETICS OF PIPERACILLIN IN FEBRILE NEUTROPENIC CANCER-PATIENTS
    DRUSANO, GL
    FORREST, A
    PLAISANCE, KI
    WADE, JC
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (06) : 635 - 641
  • [26] STEADY-STATE NONLINEAR PHARMACOKINETICS OF 5-FLUOROURACIL DURING HEPATIC ARTERIAL AND INTRAVENOUS INFUSIONS IN CANCER-PATIENTS
    WAGNER, JG
    GYVES, JW
    STETSON, PL
    WALKERANDREWS, SC
    WOLLNER, IS
    COCHRAN, MK
    ENSMINGER, WD
    CANCER RESEARCH, 1986, 46 (03) : 1499 - 1506
  • [27] Complementary pharmacokinetic measures to further define the profile of once-daily OROS hydromorphone ER during single-dose and steady-state dosing
    Devarakonda, Krishna
    Vandenbossche, Joris
    Richarz, Ute
    SPRINGERPLUS, 2013, 2 : 1 - 9
  • [28] INFLUENCE OF FOOD ON THE DISPOSITION OF THE ANTIDIABETIC DRUG METFORMIN IN DIABETIC-PATIENTS AT STEADY-STATE
    SAFFAR, F
    AIACHE, JM
    ANDRE, P
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 1995, 17 (07): : 483 - 487
  • [29] Tapentadol in Cancer Patients with Neuropathic Pain: A Comparison of Methadone, Oxycodone, Fentanyl, and Hydromorphone
    Takemura, Miho
    Niki, Kazuyuki
    Okamoto, Yoshiaki
    Matsuda, Yoshinobu
    Omae, Takahito
    Takagi, Tatsuya
    Ueda, Mikiko
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2021, 44 (09) : 1286 - 1293
  • [30] Safety, efficacy, and dosing comparison of once-daily OROS hydromorphone and immediate-release hydromorphone in patients with chronic non-cancer pain
    Bornhovd, K.
    Richarz, U.
    Berliner, M. N.
    Thipphawong, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 562 - 562
12345